agriculture 30 April 2026 State House (Uganda)
Uganda Unveils Locally Developed Anti-Tick Vaccine to Revolutionize Livestock Farming
President Yoweri Museveni has launched Uganda's first locally developed anti-tick vaccine, NAROVAC-ATV1, at the National Livestock Resources Research Institute (NaLIRRI). This innovation promises a sustainable and effective solution to tick-borne diseases that have historically plagued the nation's livestock sector. Source: https://statehouse.go.ug/president-museveni-launches-ugandas-first-anti-tick-vaccine
President Yoweri Museveni has officially commissioned Uganda’s inaugural locally manufactured anti-tick vaccine, marking a significant stride for the country’s agricultural sector. The vaccine, developed by the National Livestock Resources Research Institute (NaLIRRI), is seen as a crucial intervention against tick-borne diseases that have caused substantial losses for cattle farmers.
The Shs170 billion government-funded initiative represents a shift from traditional, often toxic acaricides to a more sustainable and effective method. “The cow now kills the tick,” President Museveni stated, highlighting the innovative mechanism of the vaccine, which empowers the animal’s immune system. This breakthrough is expected to bolster the livestock sector, especially in regions heavily impacted by tick infestations.
Officials expressed optimism about the vaccine’s potential. The Director General of the National Agricultural Research Organisation (NARO), Dr. Yonah Baguma, indicated that the vaccine is anticipated to protect Uganda’s estimated 16 million cattle. The production facility boasts a capacity of 36 million doses annually, with plans to reduce reliance on imported veterinary products and potentially become a regional supplier. Early trial farmers have reported positive outcomes, including reduced tick loads and lower treatment expenses.
The vaccine, NAROVAC-ATV1, utilizes recombinant technology with antigens derived from local tick species. It requires a specific dosage schedule for cattle over one month old, offering protection for a full year. The National Drug Authority (NDA) has confirmed the manufacturing plant meets stringent standards. At an estimated retail price of Shs10,000 per dose, the vaccine is positioned as an affordable solution for farmers, promising to enhance livestock productivity and economic benefits.
President Museveni also reaffirmed the government’s dedication to advancing Uganda’s scientific research capabilities, pledging further financial support for research hubs and considering tax incentives for scientists.
This development was made possible through collaborative efforts and sustained government investment in scientific innovation and the livestock sub-sector.
For more details, refer to the State House Uganda report.